ZDHHC5 Antibody

What are the recommended applications and dilutions for ZDHHC5 antibody?

ZDHHC5 antibody (such as 21324-1-AP) can be used in multiple applications with specific recommended dilutions for optimal results:

It's important to note that these recommendations are starting points, and the antibody should be titrated in each testing system to obtain optimal results based on the specific sample type being investigated . Published literature indicates successful applications in knock-down/knock-out validation, protein detection via western blotting, immunofluorescence, immunoprecipitation, and co-immunoprecipitation studies .

What cellular models are appropriate for ZDHHC5 antibody validation?

The ZDHHC5 antibody has been tested and validated in multiple cellular models. For western blot applications, positive detection has been reported in mouse kidney tissue, HEK-293 cells, HeLa cells, and mouse brain tissue . For immunoprecipitation, HEK-293 cells have shown reliable results, while immunofluorescence and flow cytometry have been validated in HeLa cells . When establishing new experimental systems, researchers should consider these validated models as reference points, particularly when troubleshooting antibody performance in novel tissue or cell types.

How should ZDHHC5 antibody be stored and handled to maintain optimal activity?

For optimal performance and longevity, ZDHHC5 antibody should be stored at -20°C where it remains stable for one year after shipment . The antibody is typically provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Importantly, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling protocols . Some preparations in smaller volumes (20μl) may contain 0.1% BSA as a stabilizer . Researchers should avoid repeated freeze-thaw cycles and consider preparing working dilutions fresh for each experiment to maintain consistent antibody performance.

How should researchers address discrepancies between ZDHHC5 expression and substrate palmitoylation levels?

Research has revealed complex and sometimes discordant relationships between ZDHHC5 expression levels and substrate palmitoylation. In cardiac hypertrophy and heart failure models, changes in ZDHHC5 expression did not consistently correlate with changes in palmitoylation of its substrates NCX1 and PLM . For example, in human heart failure samples, no clear relationship between ZDHHC5 expression levels and substrate palmitoylation levels was detected, despite significant changes in both parameters individually .

When designing experiments to study ZDHHC5-mediated palmitoylation, researchers should:

• Simultaneously measure ZDHHC5 expression and palmitoylation of multiple known substrates

• Consider the palmitoylation status of ZDHHC5 itself, as its activity is regulated by its own palmitoylation

• Assess subcellular localization of ZDHHC5, which may affect its ability to access and palmitoylate substrates

• Account for potential tissue-specific regulatory mechanisms

This multi-parameter approach will help distinguish between expression-dependent and regulatory effects on ZDHHC5 activity .

What controls and validation steps are critical when overexpressing ZDHHC5 in experimental models?

When designing overexpression experiments with ZDHHC5, several critical controls and validation steps should be incorporated:

• Include both wild-type ZDHHC5 and catalytically inactive mutants (such as DHHC to DHHS mutations) to distinguish enzymatic from scaffolding functions

• Verify proper subcellular localization using confocal microscopy and subcellular fractionation (e.g., sucrose gradient fractionation)

• Confirm co-localization with known membrane markers (e.g., Caveolin-3 for caveolar membranes)

• Validate functional consequences through assessment of downstream pathways or cellular phenotypes

• Quantify palmitoylation levels of known ZDHHC5 substrates to confirm enzymatic activity

Research has shown that virally expressed HA-tagged ZDHHC5 localizes to intercalated discs, cell surface, and perinuclear membranes in cardiomyocytes, with distribution to buoyant membrane fractions alongside Caveolin-3 . Proper validation ensures that experimental observations reflect authentic ZDHHC5 biology rather than artifacts of the expression system.

How should researchers interpret conflicting palmitoylation data between animal models and human samples?

Research has revealed significant discrepancies in ZDHHC5-related palmitoylation patterns between different experimental models. For instance, NCX1 palmitoylation was significantly reduced in animal models of heart failure but increased in human heart failure samples . These contradictory findings highlight several important considerations:

• Species-specific regulation of ZDHHC5 activity and substrate specificity may exist

• Disease stage and progression timeline may influence palmitoylation patterns differently across models

• Concurrent pathways affecting palmitoylation (such as depalmitoylation enzymes) may vary between species

• Human samples often reflect end-stage disease, while animal models may capture earlier phases

When designing comparative studies, researchers should:

• Include multiple time points to capture disease progression

• Directly compare multiple species using identical methodologies

• Assess both ZDHHC5 expression and its own palmitoylation status

• Consider the contribution of non-myocyte cells, which may represent approximately 25% of myocardial tissue volume

This comprehensive approach will help contextualize seemingly contradictory findings and provide deeper insights into the biological significance of observed differences.

What methodological approaches enable identification of ZDHHC5 inhibitors for cancer research?

Recent research has identified Lomitapide as a potential ZDHHC5 inhibitor with applications in pancreatic cancer treatment . The methodological approach for identifying and validating such inhibitors involves:

• Comparative transcriptomic analysis (e.g., single-cell RNA sequencing) between cancer tissues and normal tissues to establish ZDHHC5 as a potential target

• Drug repositioning screens to identify candidates with ZDHHC5 inhibitory activity

• Validation of inhibitory activity through:

  • Direct assessment of palmitoylation of known ZDHHC5 substrates (e.g., SSTR5)

  • Functional readouts of cellular pathways affected by specific palmitoylated proteins

  • Cancer cell growth and proliferation assays in vitro

  • Tumor response studies in vivo

This systematic approach has revealed that pharmacological blockade of ZDHHC5 with Lomitapide results in attenuated cancer cell growth and proliferation, contributing to antitumor responses both in vitro and in vivo . Similar methodologies can be applied to identify inhibitors relevant to other disease contexts where ZDHHC5 plays a pathological role.

How can researchers differentiate between direct ZDHHC5 inhibition and indirect effects on palmitoylation pathways?

When evaluating potential ZDHHC5 inhibitors like Lomitapide, distinguishing direct target engagement from indirect effects is crucial. Researchers should implement a multi-layered validation approach:

• In vitro enzymatic assays with purified ZDHHC5 to demonstrate direct inhibition

• Substrate-specific palmitoylation assays focusing on known ZDHHC5 targets (e.g., SSTR5, NCX1, PLM)

• Comparison with pan-palmitoylation inhibitors to establish specificity

• Rescue experiments with overexpression of ZDHHC5 or catalytically inactive mutants

• Assessment of other palmitoylation enzymes (ZDHHC family members) to rule out off-target effects

• Domain-specific binding studies to characterize inhibitor mechanism of action

This comprehensive approach will help establish whether observed phenotypic effects are truly attributable to ZDHHC5 inhibition rather than broader impacts on cellular palmitoylation machinery or completely unrelated pathways .

What are the critical considerations for translating ZDHHC5-targeted therapies from in vitro to in vivo models?

The successful translation of ZDHHC5-targeted therapies from cellular models to in vivo applications requires careful consideration of multiple factors:

• Pharmacokinetic and pharmacodynamic properties of the inhibitor, including tissue distribution and blood-brain barrier penetration if relevant

• Development of biomarkers to assess target engagement, such as measuring palmitoylation status of known ZDHHC5 substrates in accessible tissues

• Potential compensatory mechanisms through other ZDHHC family members

• Tissue-specific effects, as ZDHHC5 substrates and functions may vary across tissues

• Safety considerations related to inhibiting ZDHHC5 in non-target tissues, particularly given its known roles in cardiac tissue

• Dosing schedules that account for the dynamic and reversible nature of protein palmitoylation

How can researchers effectively measure ZDHHC5-mediated protein palmitoylation in complex tissue samples?

Measuring protein palmitoylation in complex tissues presents technical challenges that require specialized methodologies:

• Acyl-Biotin Exchange (ABE) assay: This approach involves blocking free thiols, cleaving thioester bonds with hydroxylamine, and biotinylating newly exposed thiols, followed by streptavidin pull-down and western blotting for proteins of interest

• Metabolic labeling with palmitate analogs: This can be performed in cell culture but has limitations in tissue samples

• Resin-assisted capture (RAC): Similar to ABE but uses thiol-reactive resin instead of biotin-streptavidin

• Mass spectrometry-based approaches: Provide comprehensive palmitoylome analysis but require specialized equipment

When analyzing tissue samples, researchers should calculate the palmitoylated fraction normalized to total protein (unfractionated) . Additionally, accounting for cell-type heterogeneity is crucial, as non-myocyte cells may contribute approximately 25% of myocardial tissue volume in cardiac studies . Methodological controls should include known palmitoylated proteins (e.g., Caveolin-3 or Flotillin-2) and statistical comparisons using appropriate tests such as unpaired Student's t-test.

What strategies can mitigate variability in ZDHHC5 antibody performance across different experimental systems?

Antibody performance variability is a common challenge in ZDHHC5 research. To mitigate this:

• Validation in relevant experimental systems: Test the antibody in your specific cell type or tissue before conducting full experiments

• Multiple detection methods: Combine western blotting with immunofluorescence or immunoprecipitation to confirm specificity

• Knock-down or knock-out controls: Include ZDHHC5-depleted samples to confirm antibody specificity

• Epitope mapping: Understanding the antibody's binding region helps interpret results, especially when studying truncated proteins or specific domains

• Optimized protocols for each application: Adjust blocking conditions, incubation times, and washing steps for each experimental approach

• Batch consistency: Use the same antibody lot when possible, or validate new lots against previous results

The ZDHHC5 antibody 21324-1-AP has been validated in multiple applications, including western blot, immunoprecipitation, immunofluorescence, and flow cytometry, providing a solid foundation for experimental design .

How should researchers approach contradictory data regarding ZDHHC5 function in different disease models?

Contradictory findings regarding ZDHHC5 function across disease models require systematic analytical approaches:

• Context-specific analysis: Consider disease etiology, stage, and progression when comparing models

• Multi-level investigation: Assess ZDHHC5 at genomic, transcriptomic, proteomic, and functional levels within the same study

• Substrate-specific effects: Different ZDHHC5 substrates may be affected differently in various disease contexts

• Regulatory network mapping: Identify disease-specific changes in proteins that interact with or regulate ZDHHC5

• Temporal dynamics: Capture time-course data to distinguish transient from persistent changes

• Meta-analysis approaches: Systematically compare data across multiple studies using standardized metrics

Research has demonstrated that zDHHC5 expression patterns differ between left ventricular hypertrophy and heart failure models, with elevated expression in hypertrophy but unchanged or reduced expression in heart failure . Similarly, NCX1 palmitoylation showed distinct patterns between animal models and human samples, highlighting the complexity of ZDHHC5 biology across disease contexts .

What emerging applications of ZDHHC5 antibodies show potential for advancing mechanistic understanding of disease?

Several emerging applications of ZDHHC5 antibodies show promise for deeper mechanistic insights:

• Proximity ligation assays: These can visualize interactions between ZDHHC5 and its substrates in situ, revealing spatial and temporal dynamics of palmitoylation events

• Super-resolution microscopy: Combined with ZDHHC5 antibodies, this can reveal precise subcellular localization and co-localization with substrates

• ZDHHC5 interactome mapping: Immunoprecipitation coupled with mass spectrometry can identify novel interaction partners in disease-specific contexts

• In vivo imaging: Development of labeled antibodies or fragments for non-invasive tracking of ZDHHC5 expression in disease models

• Single-cell applications: Combining ZDHHC5 antibodies with single-cell technologies can reveal cell-type specific roles in heterogeneous tissues

These approaches extend beyond traditional applications like western blotting and immunofluorescence to provide dynamic information about ZDHHC5 function in complex biological systems.

How might researchers leverage ZDHHC5 antibodies to develop biomarkers for disease diagnosis or treatment response?

ZDHHC5 antibodies may enable development of biomarkers through several approaches:

• Tissue-based diagnostics: Immunohistochemical analysis of ZDHHC5 expression and localization in biopsy samples

• Liquid biopsy applications: Detection of ZDHHC5 in circulating tumor cells or extracellular vesicles

• Companion diagnostics: Identifying patients likely to respond to ZDHHC5-targeted therapies based on expression patterns

• Treatment response monitoring: Tracking changes in ZDHHC5 expression or substrate palmitoylation during therapy

• Prognostic stratification: Correlating ZDHHC5 expression with disease outcomes in longitudinal studies

The differential expression of ZDHHC5 observed in pathological conditions such as cardiac hypertrophy and cancer suggests potential diagnostic applications . For example, the identification of ZDHHC5 as a potential target in pancreatic cancer through transcriptomic comparison between cancer and normal tissues demonstrates its biomarker potential .

What interdisciplinary approaches could resolve outstanding questions about ZDHHC5 regulation and function?

Addressing complex questions regarding ZDHHC5 regulation requires integrative approaches:

• Systems biology: Mathematical modeling of palmitoylation dynamics incorporating ZDHHC5 and its regulatory network

• Structural biology: Determining ZDHHC5 structure to understand substrate specificity and inhibitor binding

• Chemical biology: Developing chemical probes for real-time monitoring of ZDHHC5 activity

• Computational approaches: AI-driven prediction of ZDHHC5 substrates and regulatory mechanisms

• Multi-omics integration: Combining transcriptomics, proteomics, and palmitoylomics data to comprehensively map ZDHHC5 function

• Genome editing technologies: Creating precise modifications to study specific regulatory elements or protein domains

These interdisciplinary approaches could help resolve outstanding questions, such as why zDHHC5 expression changes do not consistently match changes in substrate palmitoylation, and how ZDHHC5 itself is regulated through mechanisms like palmitoylation of its C-terminal tail .